BioTime Begins PentaLyte Phase II Clinical Trial

BioTime has announced that the first surgery has been completed in its Phase II clinical trial of PentaLyte at Duke University.

PentaLyte is BioTime's proprietary pentastarch-based synthetic plasma expander and is being tested in cardiac surgery in a prospective, randomized, double-blind controlled study. PentaLyte is similar to BioTime's Hextend and is designed for use when shorter acting volume expansion is desirable.